Intravitreal Bevacizumab for Retinopathy of Prematurity: Another Hit to the Immature Lung?

Identificadores
URI: http://hdl.handle.net/10498/29411
DOI: 10.1016/j.chest.2022.06.032
ISSN: 0012-3692
Files
Statistics
Metrics and citations
Metadata
Show full item recordDate
2022-12-06Source
Chest. vol. 162, nº 6, December 2022, pp. 1231 - 1232Abstract
Laser photocoagulation has been the standard of
treatment of ROP for many years. However, since its
introduction in 2007, the use of intravitreal injection of
anti-VEGF agents has been incorporated to ROP
management. Several trials have shown that anti-VEGF
drugs (bevacizumab, ranibizumab) may be superior to
laser photocoagulation for type I ROP (zone I [any stage
with plus disease] or zone I-stage 3 without plus
disease)
Subjects
Retinopathy of prematurity (ROP); Bevacizumab; Retinopathy of PrematurityCollections
- Artículos Científicos [12014]
- Artículos Científicos INIBICA [1093]





